伊布替尼对比化疗改善伴中枢神经系统复发的套细胞淋巴瘤患者生存
这项多中心回顾性国际观察性研究纳入2000至2019年间88例中枢神经系统复发的套细胞淋巴瘤患者,比较伊布替尼(29例)与透过血脑屏障化疗(29例)的结局;伊布替尼组中位总生存16.8个月对比4.4个月(P=0.007),中位无进展生存13.1个月对比3.0个月(P=0.009)。
要点
- 中位总生存:伊布替尼组16.8个月对比透过血脑屏障化疗组4.4个月(P=0.007)。
- 中位无进展生存:伊布替尼组13.1个月对比透过血脑屏障化疗组3.0个月(P=0.009)。
- 多因素分析中伊布替尼是最强的独立有利预测因素。
核心结论
- 在伴中枢神经系统复发的套细胞淋巴瘤患者中,伊布替尼与透过血脑屏障化疗相比,与更优的生存相关,应考虑作为治疗选择。
研究设计与样本
- 多中心回顾性国际观察性研究,代表意大利淋巴瘤基金会和欧洲套细胞淋巴瘤网络开展,招募2000至2019年间接受中枢神经系统导向治疗的伴中枢神经系统复发的套细胞淋巴瘤患者,共纳入88例。
- 采用基于多变量二元回归模型的倾向性评分平衡治疗队列。
主要发现
- 入组时中位年龄65岁(范围39-87),76%为男性,从淋巴瘤诊断至中枢神经系统复发的中位时间16个月(范围1-122)。
- 患者接受伊布替尼(n=29,伊布替尼队列)、透过血脑屏障化疗(即大剂量甲氨蝶呤±阿糖胞苷;n=29,透过血脑屏障队列)或其它治疗(n=30,其它治疗队列)。
- 伊布替尼队列与透过血脑屏障队列相比,中位总生存(16.8个月对比4.4个月;P=0.007)和中位无进展生存(13.1个月对比3.0个月;P=0.009)均更优。
- 多变量Cox回归模型显示,伊布替尼治疗选择是总生存(风险比[HR] 6.8;95%置信区间[CI] 2.2-21.3;P<0.001)和无进展生存(HR 4.6;95%CI 1.7-12.5;P=0.002)最强的独立有利预测因素,其次是首次套细胞淋巴瘤诊断后中枢神经系统疾病进展>24个月(死亡HR 2.4;95%CI 1.1-5.3;P=0.026;死亡或进展HR 2.3;95%CI 1.1-4.6;P=0.023)。
- 在全身中枢神经系统导向治疗基础上加用鞘内化疗与总生存更优无关(P=0.502),形态学变异型(经典型对比其它,P=0.118)亦无关。
关键数值与推荐
- 伊布替尼队列:中位总生存16.8个月 vs 透过血脑屏障队列4.4个月(P=0.007),中位无进展生存13.1个月 vs 3.0个月(P=0.009)。
- 伊布替尼治疗选择:总生存HR 6.8(95%CI 2.2-21.3;P<0.001),无进展生存HR 4.6(95%CI 1.7-12.5;P=0.002)。
- 首次套细胞淋巴瘤诊断后中枢神经系统疾病进展>24个月:死亡HR 2.4(95%CI 1.1-5.3;P=0.026),死亡或进展HR 2.3(95%CI 1.1-4.6;P=0.023)。
临床怎么用
- 作者认为,在伴中枢神经系统复发的套细胞淋巴瘤患者中,伊布替尼与透过血脑屏障化疗相比与更优的生存相关,应考虑作为治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Central nervous system (CNS) relapse of mantle cell lymphoma (MCL) is a rare phenomenon with dismal prognosis, where no standard therapy exists. Since the covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in relapsed/refractory MCL and penetrates the blood-brain barrier (BBB), on behalf of Fondazione Italiana Linfomi and European Mantle Cell Lymphoma Network we performed a multicenter retrospective international study to investigate the outcomes of patients treated with ibrutinib or chemoimmunotherapy. In this observational study, we recruited patients with MCL with CNS involvement at relapse who received CNS-directed therapy between 2000 and 2019. The primary objective was to compare the overall survival (OS) of patients treated with ibrutinib or BBB crossing chemotherapy. A propensity score based on a multivariable binary regression model was applied to balance treatment cohorts. Eighty-eight patients were included. The median age at study entry was 65 years (range, 39-87), 76% were males, and the median time from lymphoma diagnosis to CNS relapse was 16 months (range, 1-122). Patients were treated with ibrutinib (n = 29, ibrutinib cohort), BBB crossing chemotherapy (ie, high-dose methotrexate ± cytarabine; n = 29, BBB cohort), or miscellaneous treatments (n = 30, other therapy cohort). Both median OS (16.8 vs 4.4 months; P = .007) and median progression-free survival (PFS) (13.1 vs 3.0 months; P = .009) were superior in the ibrutinib cohort compared with the BBB cohort. Multivariable Cox regression model revealed that ibrutinib therapeutic choice was the strongest independent favorable predictive factor for both OS (hazard ratio [HR], 6.8; 95% confidence interval [CI], 2.2-21.3; P < .001) and PFS (HR, 4.6; 95% CI, 1.7-12.5; P = .002), followed by CNS progression of disease (POD) >24 months from first MCL diagnosis (HR for death, 2.4; 95% CI, 1.1-5.3; P = .026; HR for death or progression, 2.3; 95% CI, 1.1-4.6; P = .023). The addition of intrathecal (IT) chemotherapy to systemic CNS-directed therapy was not associated with superior OS (P = .502) as the morphological variant (classical vs others, P = .118). Ibrutinib was associated with superior survival compared with BBB-penetrating chemotherapy in patients with CNS relapse of MCL and should be considered as a therapeutic option.
引用
- Rusconi C, Cheah CY, Eyre TA, et al. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood. 2022. PMID: 35789260. doi:10.1182/blood.2022015560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。